Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Instagram Outage Disrupts Thousands of U.S. Users 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
FORT LAUDERDALE, Fla., April 11, 2016 -- OmniComm Systems, Inc. (OmniComm) (OTCQX:OMCM), a global leading provider of clinical data management technology, today announced the signing an agreement with Medistat Ltd., a leading data management and biostatistics organization, headquartered in Tel Aviv, Israel. OmniComm’s TrialMaster electronic data capture (EDC) suite will be used to address the clinical trial needs of the growing Israeli life sciences sector which consists of more than 1300 organizations.
“We are pleased that OmniComm Systems is realizing the value of the Israeli market and the position of Medistat as a global provider of data management and biostatistician solutions,” said Dr. Gil Harari President and CEO of Medistat, “We truly believe that the cooperation with OmniComm will be a key factor to becoming a leader in the rapidly growing Intelligent EDC market in Israel and worldwide.”
TrialMaster was selected for its inherent flexibility, scalability, data quality and broad capabilities. These criteria were especially important to Medistat as they support the needs of the burgeoning pharmaceutical and biotechnology industry. To build their studies, Medistat selected TrialMaster’s rich and versatile design and build toolset that makes study builds easier to learn and easier to work with, enabling faster study build times when compared to other competing technologies.
Additional capabilities that were germane to their decision include:
- TrialMaster Custom Data Export Utility to create CDISC SDTM submission ready data
- Ad hoc reporting to create and share dashboards, reports, and analysis
- Risk-based monitoring to centrally monitor key risk indicators (KRIs) and identify emerging risks across sites and subjects
Having TrialMaster has already aided Medistat gain additional data management business with existing and new clients.
OmniComm and Medistat strategic partnership includes co-sponsorship at the Annual Meeting of the Clinical Trials Community in Israel, April 11, 2016. OmniComm will address the conference attendees with the presentation entitled “Intelligent EDC Solutions. Risk-Based Monitoring and Safety Link.”
“We are delighted that TrialMaster was chosen by Medistat as their preferred EDC solution,” said Kuno van der Post, SVP of business development, OmniComm Systems. “We view the Israeli market as a key region for OmniComm’s growth and through our strategic partnership with Medistat we now have a stronger offering for our clients.”
About Medistat
Medistat Ltd. specializes in biostatistics and data management, operating since 1995. It provides a wide range of related services to clients that conduct and manage biomedical research. The core services of Medistat are clinical trials data management and biostatistical analysis. Medistat is committed to providing all its clients with comprehensive solutions for planning, managing, and analyzing their clinical trials. For more information, visit http://www.medistat.co.il.
About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies these organizations drive efficiency in clinical development, better manage their risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from over 4,000 clinical trials. For more information, visit www.omnicomm.com.
Trademarks
OmniComm, TrialMaster, TrialOne, and Promasys are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.
Contact Info
Dennis Constantinou
OmniComm Systems, Inc.
+1.954.473.1254
[email protected]
